Antibodies are the cardinal effector molecules of the immune system and are being
leveraged with enormous success as biotherapeutic drugs. A key part of the adaptive …

Antibodies and antibody-derived macromolecules have established themselves as the
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …

Antibodies are the most rapidly growing drug class and have a major impact on human
health, particularly in oncology, autoimmunity and chronic inflammatory diseases. Many of …

Antibodies and Fc-fusion antibody-like proteins have become successful biologics
developed for cancer treatment, passive immunity against infection, addiction, and …

The majority of monoclonal antibody (mAb) therapeutics possess the ability to engage
innate immune effectors through interactions mediated by their fragment crystallizable (Fc) …

Therapeutic monoclonal antibodies are among the most effective biotherapeutics to date. An
important aspect of antibodies is their ability to bind antigen while at the same time recruit …

Bispecific antibodies are on the cusp of coming of age as therapeutics more than half a
century after they were first described. Two bispecific antibodies, catumaxomab (Removab® …

Antibody-based proteins have become an important class of biologic therapeutics, due in
large part to the stability, specificity, and adaptability of the antibody framework. Indeed …

Combination antiretroviral therapy (ART) can block multiple stages of the HIV-1 life cycle to
prevent progression to AIDS in people living with HIV-1. However, owing to the persistence …

Anti–CTLA-4 mAb is efficacious in enhancing tumor immunity in humans. CTLA-4 is
expressed by conventional T cells upon activation and by naturally occurring FOXP3+ CD4+ …